key: cord-0883642-0tsefy6p
authors: Orioli, Laura; Hermans, Michel P; Thissen, Jean-Paul; Maiter, Dominique; Vandeleene, Bernard; Yombi, Jean-Cyr
title: COVID-19 in diabetic patients: related risks and specifics of management
date: 2020-05-12
journal: Ann Endocrinol (Paris)
DOI: 10.1016/j.ando.2020.05.001
sha: f2690a25f9983ab677cab18b4bfce9063e425a8a
doc_id: 883642
cord_uid: 0tsefy6p

Abstract Diabetes is among the most frequently reported comorbidities in patients infected with COVID-19. According to current data, diabetic patients do not appear to be at increased risk of contracting SARS-CoV-2 compared to the general population. On the other hand, diabetes is a risk factor for developing severe and critical forms of COVID-19, the latter requiring admission to an intensive care unit and/or use of invasive mechanical ventilation, with high mortality rates. The characteristics of diabetic patients at risk for developing severe and critical forms of COVID-19, as well as the prognostic impact of diabetes on the course of COVID-19, are under current investigation. Obesity, the main risk factor for incident type 2 diabetes, is more common in patients with critical forms of COVID-19 requiring invasive mechanical ventilation. On the other hand, COVID-19 is usually associated with poor glycemic control and a higher risk of ketoacidosis in diabetic patients. There are currently no recommendations in favor of discontinuing antihypertensive medications that interact with the renin-angiotensin-aldosterone system. Metformin and SGLT2 inhibitors should be discontinued in patients with severe forms of COVID-19 owing to the risks of lactic acidosis and ketoacidosis. Finally, we advise for systematic screening for (pre)diabetes in patients with proven COVID-19 infection.

Owing to the health emergency, knowledge about COVID-19 is growing rapidly.

Diabetes is among the most frequently reported comorbidities in patients infected with COVID-19. The characteristics of diabetic patients at risk for developing severe and critical forms of COVID-19, as well as the prognostic impact of diabetes on the course of COVID-19, are under investigation. Pending for the results of these dedicated studies, this article summarizes current data on the clinical presentation and risks of COVID-19 in diabetic patients. We also provide some recommendations for the management of diabetic patients with COVID-19.

Testing conditions for diagnosing COVID-19 infection depend on national policies and capacities. They have changed over time in various countries including Belgium, making comparisons between available data difficult. Initially, shortage of test reagents prompted Belgian authorities to limit testing to suspected cases of acute infection requiring hospitalization. RT-qPCR testing has now been extended to symptomatic caregivers and residents of nursing homes since April 10, 2020, and to any possible case defined by compatible symptoms since May 4, 2020 [6] . Moreover, local procedures have recently included a category of "radiologically confirmed" cases based on suggestive CT-scans [6] .

Data released by Sciensano, the Belgian Institute for Health, should thus be interpreted cautiously, according to these limitations in screening and diagnostic procedures. In France, diagnostic testing has been more broadly performed in any symptomatic individual among the caregivers, the elderly, patients with comorbidities and/or patients with respiratory difficulties, as well as hospitalized patients since the epidemic was declared [10] . In April 2020, screening campaigns targeting the elderly, people with disabilities as well as their caregivers were also performed. Testing should next be extended to any symptomatic person and their close contacts [10].

In Belgium, comorbidities have been reported only from hospitalized patients most of whom had severe or critical forms of COVID-19 [6] . In these patients, the mean prevalence of preexisting diabetes reached 21.1% on April 30, 2020 ( Table 1 ). This figure is more than 3fold higher than the 6% prevalence found in the general adult population (aged ≥ 15 years), reported by both the latest national Health Survey carried out in 2018 [1] and the IDF in 2016 [3] . As expected, the prevalence of diabetes in patients with COVID-19 rises with age but remains higher than that of the 2018 Health Survey ( Table 1) .

Insert Table 1 Chinese, Italian and American studies also showed that diabetes is among the most frequently reported comorbidities in patients infected with COVID-19, with a prevalence ranging from 3 to 25% in non-critical forms of the infection [11] [12] [13] [14] [15] [16] . In meta-analyzes of Chinese studies, the mean prevalence of diabetes among patients with COVID-19 was 8 to 10% [17, 18] .

In Europe, an Italian team from Padua reported a prevalence of 8.9% in hospitalized patients with COVID-19 [17] . These results are comparable to those usually observed in the general population of these regions [2] , which would suggest that diabetic patients are not at increased risk for contracting COVID-19.

Although diabetic patients are considered at higher risk for contracting infections, recent studies have shown that these are mainly fungal and bacterial, particularly soft tissue infections, urinary tract infections and community acquired pneumonia (including pneumococcal pneumonia) [19] . Viral infections, such as seasonal flu, are as frequent in diabetics as in the general population, although diabetes is a risk factor for developing severe or critical forms of these infections [20, 21] .

Regarding viral infections, a recent study showed that diabetes was a risk factor for developing severe and critical pneumonia due to influenza A [21] . The epidemics of SARS and MERS have also shown that diabetic patients and, more broadly, patients with comorbidities such as hypertension, cardiovascular disease and obesity, are at increased risk for developing severe and fatal forms of coronavirus pneumonia [9] .

Regarding COVID-19, it seems already well-established that diabetes represents a risk factor or a risk marker for developing severe and critical forms of the infection [18] . Severity criteria, defined by the Chinese National Health Committee, include tachypnea (respiratory rate ≥30/minute), oxygen saturation ≤93% at rest, and/or an oxygenation index ≤300mmHg and/or lung infiltrates >50% developing over 24-48 hours. Severe forms require supportive therapy with oxygen, while critical forms include the onset of ARDS (Acute Respiratory Distress Syndrome), shock, and/or multi-organ failure, all requiring admission to an ICU and invasive procedures. These severe and critical forms of COVID-19 are more frequent in elderly patients (>60 years) with one or more underlying chronic conditions [8, [11] [12] [13] [14] [15] [16] [22] [23] [24] [25] [26] . Beside diabetes, hypertension and cardiovascular disease are the most frequently reported comorbidities ( Table 2 ) [27] .

Insert Table 2 While the prevalence of diabetes among patients with COVID-19 varies from one study to another, reaching that of the general population in certain studies, there are twice as many diabetic patients among those who progress to a severe form of the infection or die from it [17, 18] . According to Chinese data, the prevalence of diabetes in patients with a critical form of COVID-19 ranges from 15 to 25%, a figure 2 to 4-fold higher than that in non-critical patients [22] [23] [24] . A prevalence exceeding 50% was even reported in the United States in patients admitted to ICU for a critical form of COVID-19 [26] . Such data are not yet available in Belgium and France.

Whereas diabetic patients seem more at risk of developing severe or critical forms of COVID-19, the respective roles of diabetes per se, chronic hyperglycemia (with glycated hemoglobin (HbA1c) as proxy), insulin deficiency and/or resistance, obesity, and other comorbidities are not yet understood. Only a single study compared the clinical presentation of COVID-19 between diabetic (with or without comorbidities) and non-diabetic patients [28] . This Chinese study provided some noteworthy data.

First, the infection appears to present initially with milder symptoms in diabetic patients.

Thus, fever was less frequent, which could delay initial diagnosis. Second, analysis of chest CT-scans revealed more severe pneumonia in patients with diabetes. Third, diabetic patients (especially those without comorbidity) had more pronounced biological abnormalities, including elevated inflammatory biomarkers (eg. C-reactive protein (CRP) and interleukin 6 (IL6)), elevated tissue enzymes (eg. lactate dehydrogenase (LDH)), and clotting abnormalities (eg. elevated D-dimer). According to the authors, these abnormalities are related to severe multi-organ damage and to a propensity to thromboembolic events, as well as to the "cytokine storm" described as an aggravating factor of COVID-19 [33] . Finally, lymphopenia, frequently reported as marker of poor prognosis [8, 13, 15] , was more frequent and more severe in diabetic patients. Although interesting, these data require confirmation from other studies, including data in other Caucasian and non-Caucasian populations, due to methodological limitations discussed below.

Mortality due to COVID-19 varies from one study to another, ranging from 2 to 15% in severe forms [11] [12] [13] [14] [15] [16] , to more than 20% and even 50% in critical forms [22] [23] [24] [25] [26] . In Belgium, the overall mortality ascribed to COVID-19 has been reported jointly for hospitalized and nonhospitalized patients. At the time of writing this article, the case fatality rate in Belgium reached 15% of diagnosed individuals (representing an incidence rate of 68.7/100.000 inhabitants); 45% of deaths occurred in hospitals and 55% in home care facilities [5, 6] . Again, these figures should be interpreted with caution, according to the known limitations regarding screening and diagnostic testing as well as inclusion of suspected yet unconfirmed death cases ascribed to the virus especially in homes care facilities. By comparison, the case fatality rate reached 19% of diagnosed individuals in France (incidence rate of 37.2/100.000 individuals), 63% of deaths occurring in hospitals and 37% in home care facilities [5, 10] . However, overall mortality due to COVID-19 is lower as all affected patients did not undergo testing. According to published data by the European Center for Disease Prevention and Control, worldwide case fatality rate is currently 7% [5] and universal screening should likely further decrease these estimates.

What about mortality in diabetics? According to Chinese data on more than 70,000 cases, the overall mortality linked to COVID-19 was 2.3% versus 7.3% in diabetic patients [29] .

In addition, the prevalence of diabetes reached 20 to 30% in non-survivors, a figure up to 3fold higher than that in surviving patients [17, 27] . The prevalence of outcomes in diabetic patients including severe disease, admission to an ICU and death are shown in Figure 1 . Such data are not yet available in France and Belgium.

Insert Figure 1 Diabetic patients clearly appear at increased risk of dying from COVID-19 [18] .

However, the impact of diabetes per se as a prognostic risk factor or marker should be better understood, as the majority of patients with severe and critical forms of COVID-19 had multiple comorbidities also associated with increased odds for developing severe COVID-19 infection or death [23, 27, 31, 34] . According to Chinese and Italian studies, most of the severely ill or deceased patients with COVID-19 had more than 2 or 3 chronic underlying diseases [31, 34] .

Guan et al reported that the odds of severe outcomes including admission to an ICU and/or use of IMV and/or death in patients with COVID-19 were 1.79 (95% CI 1.16-2.77) among those with at least one comorbidity, and 2.59 (95%CI 1.61-4.17) among those with ≥ 2 comorbidities [34] .

In the study of Guo et al [28] , diabetic patients died much more often than nondiabetic patients (10.8% versus 3.6%). However, mortality rates were similar among non-diabetic and diabetic patients with comorbidities, despite a higher prevalence of cardiovascular disease in the latter (32% versus 15%). On the other hand, diabetic patients without comorbidity died more often than non-diabetic patients (16% versus 0%), with the caveat that they were much older (median age 61 years versus 32 years).

The prognostic impact of diabetes should therefore be clarified in more robust studies taking all confounders into account.

Why would diabetes per se negatively influence the prognosis of COVID-19 infection? Diabetes and hyperglycemia were identified as factors that negatively influence the prognosis of sepsis and pneumococcal pneumonia, as well as that of SARS, MERS and H1N1 influenza [9] . The impact of diabetes and obesity was studied in a transgenic mouse model expressing the human DDP4, the entry receptor of MERS-CoV [35] . Transgenic diabetic mice with MERS-CoV infection showed more severe viral pneumonia and lung injury characterized by delayed initiation of inflammation and slower inflammatory resolution. These findings suggest that a dysregulated immune response is the basis of increased coronaviruses infection severity in diabetics. In vitro studies showed indeed that hyperglycemia alters innate immunity, induces endothelial dysfunction and promotes a pro-coagulant state [19] . In vivo studies also showed that hyperglycemia prolongs the duration of the cytokine response triggered by infection in mouse models of diabetes [19] . Finally, in vitro hyperglycemia alters the pulmonary epithelium and promotes infection with the influenza virus [9] . Although the clinical relevance of these preclinical data must be confirmed, especially in the context of SARS-CoV-2 infection, they could explain the severity of the biological and radiological picture described by Guo 

From a diabetologist's point of view, the studies published to date did not provide data on the type and duration of diabetes, glucose-lowering drugs, and chronic glycemic control (HbA1c) prior to admission. These data would make it possible to identify among diabetic patients those at higher risk of developing severe and critical forms of COVID-19. Of ongoing studies, the CORONADO survey (Coronavirus SARS-CoV2 and Diabetes Outcomes) should provide these much-needed data. This French multi-center study, supported by the Frenchspeaking Diabetes Society (Société Francophone du Diabète, SFD), was recently launched and will include more than 300 diabetic patients. One may however anticipate that older and/or obese patients with poorly-controlled T2DM and/or micro-and macrovascular complications should be more severely affected by COVID-19 than younger patients with uncomplicated diabetes and good glycemic control.

Obesity, a major risk factor for incident T2DM, was already reported to be a risk factor of poor prognosis in patients with COVID-19. The higher mortality rates related to COVID-19 reported in Italy (compared to those in China) could be explained, at least in part, by a higher prevalence of obesity in elderly patients from the peninsula [36] . Indeed, a Chinese study found that the body mass index (BMI) of critically ill patients with COVID-19 was higher than that of non-critical patients (25.5 kg/m² versus 22.0 kg/m²) [37] . Moreover, the prevalence of overweight and obesity in this study was higher in non-survivors compared to survivors (88% versus 19%) [37] . Another Chinese study (not peer-reviewed at the time of writing this report)

reported that overweight and obesity might be associated with an increased risk of developing severe pneumonia in patients with COVID-19 [38] . These associations might be more pronounced in men in whom overweight and obesity were respectively associated with a 1.96-fold and 5.7-fold increased risk, compared to a 1.51-fold and a 0.71-fold risk in women [38] . A French study (Lille) showed a high prevalence of obesity (48%) among patients with COVID-19 admitted to the ICU as well as an increasing requirement of IMV according to BMI [39] . In this study, 86% of patients with severe or morbid obesity (BMI ≥ 35 kg/m²) required IMV, against 47% of patients with normal weight (BMI <25 kg/m²). In Belgium, the mean prevalence of obesity in hospitalized patients with COVID-19 reached 10.5% (Table 1) , a figure surprisingly lower than the 16% prevalence found in the general population, as reported in the 2018 Health Survey [1, 6] . In contrast, obesity was reported in 36% to 50% of hospitalized patients with COVID-19 in the United States [16, 40, 41] whereas the prevalence of obesity reached 35% in the general population in 2016 according to the WHO [2] . In Italy, the prevalence of obesity and T2DM among patients who died from COVID-19 did not differ between women and men, respectively 31.4% versus 31.9% and 12.7% versus 11.0% [31] . 66 .7%, respectively, in the general population of these countries [2] . A first link between body weight excess and severity of COVID-19 infection is the negative impact of obesity on the pulmonary function, including reduced expiratory reserve, functional capacity, and respiratory system compliance; as well as decreased diaphragmatic movements with abdominal obesity in supine position [36] . Inflammation might be a second link between obesity and severe forms of COVID-19. Indeed, the risk for developing ARDS as well as the outcomes of ARDS have been linked to a series of genes and their variants including those coding for pro-inflammatory cytokines (such as IL-6), chemokines and ACE [47] while obesity is associated with low-grade systemic inflammation and elevated plasma levels of pro-inflammatory cytokines (such as IL-6) and complement overactivation [36] . Moreover, epicardial fat whose volume is increased in obese individuals and lung adipocytes might play a role in cardiac and lung injuries caused by COVID-19 [45, 46] . Available data regarding obesity in patients with COVID-19 are summarized in Table 3 .

Insert Table 3 1

Hyperglycemia may precede the symptoms of COVID-19 and predispose to acute metabolic complications, such as ketoacidosis and hyperosmolar coma. Moreover, COVID-19 infection can also present with digestive symptoms such as vomiting and diarrhea leading to dehydration. According to a Chinese study including 29 T2DM patients, hyperglycemia was frequent over the course of COVID-19 infection [48] . Another Chinese study showed that COVID-19 infection was associated with ketoacidosis in 12% of diabetic patients [49] .

Hyperglycemia and insulin resistance are frequent in critically-ill patients. They results from the release of counterregulatory hormones such as glucagon, cortisol and epinephrine as well as increased circulating levels of proinflammatory cytokines such as IL-6 and TNFa which contribute to the cytokine storm [33] . Their action on insulin-sensitive tissues results in decreased muscle glucose uptake, enhanced lipolysis, and increased hepatic glucose output [50] .

Given the harmful effects of hyperglycemia (even transient) on innate immunity [19] , strict monitoring and control of blood glucose must be part of the management of diabetic patients with COVID-19. A recently published Chinese study showed that a well-controlled blood glucose, maintaining glycemic variability between 0.70g/L and 1.8g/L, in type 2 diabetic patients with COVID-19 was associated with a reduction of the 28-day all-cause mortality as well as the development of ARDS, acute kidney injury and acute cardiac injury [51] . Although intensive insulin therapy was previously shown to improve both mortality and morbidity of diabetic and non-diabetic patients admitted in the ICU [52] , hypoglycemia induced by intensive insulin therapy was identified as an independent risk factor of death in patients with critical medical conditions including sepsis and bacteremia [53] . The potentially deleterious effects of too tight a glycemic control, predisposing to hypoglycemia in both diabetic and non-diabetic patients admitted to ICU, was further confirmed in multicenter studies [54] . Metformin and SGLT2 inhibitors should be discontinued in severe forms of COVID-19, given their intrinsic risk of lactic acidosis and ketoacidosis, respectively. Practical recommendations for the management of diabetes in patients with COVID-19 were recently published [55] .

Concerns are also rising regarding the risk of incident diabetes after recovery from mild, asymptomatic or severe COVID-19 infection. Indeed, it is commonly admitted that certain viral diseases can trigger autoimmune type 1 diabetes in genetically susceptible patients, or even produce fulminant diabetes from mass collapse of β cells. COVID-19 makes use of the Angiotensin Converting Enzyme type 2 (ACE2) receptor as "gateway" to invade target cells in humans [56] . This enzyme is expressed by different tissues and cell types, including the lungs as well as the endocrine pancreas [56] . A Chinese study has suggested that infection with SARS-CoV, which also uses ACE2 receptor as entry receptor, could damage the islets of Langerhans, causing hyperglycemia over the course of infection [57] . In contrast, this study did not demonstrate an increased risk of diabetes in the long term. Another Chinese study reported pancreatic injury assessed by elevations of plasma amylase and lipase levels in 17% of patients with COVID-19, among whom 67% had moderately elevated plasma glucose [58] . The question remains therefore open regarding COVID-19 and risk of new-onset diabetes.

Finally, the hyper-or hypoglycemic impact of treatments administered for the management of COVID-19 infection must be taken into account, beside the well-known hyperglycemic effect of glucocorticoids. While the benefits and indications of hydroxychloroquine in the treatment of COVID-19 are still under investigation, it is worth keeping in mind that this molecule has hypoglycemic effects and is used in India as alternative glucose-lowering agent [59] . The mechanisms underlying this hypoglycemic effect are poorly understood; a series of complex molecular effects may both improve insulin sensitivity and insulin secretion. The dosages of glucose-lowering drugs, including insulin, should be adjusted accordingly.

While the well-known angiotensin-converting enzyme 1 (ACE1) promotes the conversion of angiotensin I (AT-I) to angiotensin II (AT-II), its homologous counterpart ACE2 is a membrane-bound carboxypeptidase which normally contributes to AT-II inactivation, and therefore physiologically counters RAAS activation [56, 58, 60] . ACE2 also acts as the receptor that allows entry of emergent coronaviruses (SARS-CoV-2 and SARS-CoV) into human cells [56] . The SARS-CoV-2 spike-protein, once bound to ACE2, is activated by the type II transmembrane serine protease (TMPRSS2) to promote invasion and viral replication within targets human cells, including type II pneumocytes [56] . ACE inhibitors (ACEI) typically inhibit ACE1 but not ACE2 [61] . On the other hand, ACE2 exerts a critical role in maintaining glucose homeostasis and Bcell function [58, 62] . Preclinical studies have shown that diabetes alters the activity and/or expression of ACE2 in the serum and tissues of different murine models [58, 62, 63] . As an example, rats with streptozotocin-induced diabetes have a reduced pulmonary expression of ACE2 mRNA while NOD mice, developing spontaneously auto-immune diabetes mimicking type 1 diabetes, have increased expression of ACE2 in both the lung and the heart [58, 63] . Yet the relevance of such findings in the context of SARS-CoV-2 infection needs clarification.

RAAS inhibitors are widely used in patients with diabetes and hypertension.

RAAS inhibitors might increase the tissue expression of ACE2, thus raising theoretical concerns about increased infectivity of SARS-CoV-2 and poorer prognosis of infected patients on RAAS blockers [60, 64] . Yet currently published studies did not find increased infectivity of COVID-19 in patients with previous treatment with RAAS inhibitors. Indeed, a population-based case-control study performed in Italy (Lombardy) including more than 6000 patients, did not find any evidence that RAAS inhibitors affected the risk of COVID-19 [64] .An observational study including more than 12.500 patients tested for COVID-19 in New York also did not find an association between previous treatment with RAAS inhibitors and higher risk of testing positive for COVID-19 [65] . Moreover, these molecules could also have beneficial effects in patients with lung injury caused by COVID-19. Preclinical data showed that mice infected with SARS-CoV and receiving losartan had reduced lung injury compared to untreated mice [9, 60] . This protective effect was associated with an increased expression of ACE2 in response to losartan [9, 60] . In humans, studies reported decreased mortality and lesser requirement of IMV in patients with viral pneumonia receiving RAAS blockers [9] . RAAS blockers could have beneficial immunomodulatory effects at systemic and pulmonary levels by decreasing cytokines [9] . A retrospective Chinese study of 112 patients with prior cardiovascular disease and SARS-CoV-2 infection showed the same proportion of patients taking RAAS blockers among survivors and non-survivors [37] . The benefit of maintaining RAAS blockers prescribed for chronic cardiovascular and/or chronic renal diseases might exceed their potential harm in patients with COVID-19 as RAAS inhibitors might protect against organ and myocardial injury caused by SARS-CoV-2 [60] . A recent Chinese study showed a lower risk of all-cause mortality in hospitalized patient with both COVID-19 and hypertension receiving RAAS blockers compared to non-treated patients [66] . Moreover, RAAS inhibitors were not associated with higher risk of severe COVID-19 neither in Lombardy nor in New York [64, 65] . Thus, overall, the current recommendation is to continue RAAS inhibitors in both diabetic and non-diabetic patients during acute COVID-19 infection [60,64-66].

Several experimental data suggest that glucose-lowering drugs used in diabetic patients may impact the pathophysiology of COVID-19. The glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide was shown to counteract the downregulating effect of diabetes on the pulmonary expression of ACE2 in rats without influencing glucose and insulin levels [58] . GLP-1-RAs were also shown to have anti-inflammatory effects and to reduce lung inflammation in murine models of experimental lung injury [58] . In humans, GLP-1 RAs reduce circulating inflammatory biomarkers in diabetic and/or obese patients while insulin reduces these biomarkers in critically-ill patients [58] . Pioglitazone was also shown to upregulate ACE2 in hepatocytes of rats fed a high J o u r n a l P r e -p r o o f 13 fat diet [9] . Finally, the dipeptidyl peptidase-4 (DPP-4) is the entry receptor of MERS-CoV, raising concerns about the impact of DPP-4 inhibitors during the course of coronavirus infection [9] . Yet the clinical relevance of these preclinical and human data in the context of SARS-CoV-2 infection needs clarification [67] . As for the GLP-1 RA, they have been safely used for blood glucose control in critically ill and ventilated patients in short term studies [58] ; but there is insufficient hindsight to recommend their use in diabetic patients with COVID-19 [67] .

T2DM can remain asymptomatic for many years before diagnosis. It is often diagnosed incidentally or at the time of occurrence of chronic complications. Despite the limitations of currently available data regarding the impact of diabetes on the prognosis of COVID-19, it is plausible that a hitherto undiagnosed T2DM, in addition to age and other comorbidities, is a risk factor of poor prognosis. We advise therefore for systematic screening of unrecognized (pre)diabetes, using HbA1c on admission, in all patients hospitalized for COVID-19, and more broadly, in any patient with proven COVID-19 infection. 

From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVID-19 and diabetes: Knowledge in progress

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of Covid-19 in New York City

Prevalence and impact of diabetes among people infected with SARS-CoV-2

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -A systematic review, meta-analysis, and meta-regression

Diabetes and sepsis: preclinical findings and clinical relevance. Diabetes Care

Association between glycaemic control and common infections in people with Type 2 diabetes: a cohort study

Influenza A-associated severe pneumonia in hospitalized patients: Risk factors and NAI treatments

He JX et al; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations

Diabetes is a risk factor for the progression and prognosis of COVID-19

Epidemiology Working Group for NCIP Epidemic Response. The epidemiological characheristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China

Care-fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Covid-19 surveillance group

Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 -United States

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

China Medical Treatment Expert Group for Covid-19. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis

Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight

Obesity and its Implications for COVID-19 Mortality. Obesity (Silver Spring)

Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China (3/13/2020)

The Lille Intensive Care COVID-19 and Obesity study group. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation

Preliminary data of the prevalence of selected underlying medical conditions among patients with COVID-19 laboratory-confirmed hospitalizations

Association of Obesity with Disease Severity among Patients with COVID-19. Obesity (Silver Spring)

ICNARC report on COVID-19 in critical care. 2020. www.icnarc.org

Obesity is associated with severe forms of COVID-19. Obesity (Silver Spring)

Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission

Obesity accompanying COVID-19: the role of epicardial fat

The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections. Obesity (Silver Spring)

Fifty Years of Research in ARDS. Genomic Contributions and Opportunities

Diabetes patients with Covid-19 need better blood glucose management in Wuhan

COVID-19 infection may cause ketosis and ketoacidosis

Insulin resistance and hyperglycemia in critical illness: role of insulin in glycemic control

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

Intensive insulin therapy in critically ill patients

Intensive insulin therapy in the medical ICU

Intensive versus conventional glucose control in critically ill patients

Practical recommendations for the management of diabetes in patients with COVID-19

SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues

Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes

Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

Drugs, COVID-19' working group of the French Society of Pharmacology, Therapeutics. Renin-angiotensin-aldosterone system and COVID-19 infection

ACE2 deficiency reduces β-cell mass and impairs β-cell proliferation in obese C57BL/6 mice

Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19

Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?

COPD, chronic obstructive pulmonary disease

CKD, chronic kidney disease

intensive care unit ; IMV :invasive mechanical ventilation ; NR, non-reported

Type 2 diabetes; $ ischemic heart disease Criteria for severe infection were based either on the guideline of the Chinese National Health Committee, the WHO interim guidance or the American Thoracic Society* guidelines for community-acquired pneumonia. Criteria of the Chinese National Health Committee include: respiratory rate ≥ 30/minute and/or pulse oximeter oxygen saturation ≤93% at rest and/or oxygenation index ≤300mmHg and/or lung infiltrates > 50% developing over 24-48 hours. Criteria of the WHO include: respiratory rate > 30/minute and/or severe respiratory distress and/or or pulse oximeter oxygen saturation ≤93% at rest. Criteria of the American Thoracic Society* guidelines for community-acquired pneumonia include: minor criteria (≥3): respiratory rate >30/minute, oxygenation index ≤250mmHg, multilobar infiltrates, confusion/disorientation, uremia (blood urea nitrogen level ≥20 mg/dl), leukopenia (white blood cell count <4,000 cells/ml), thrombocytopenia (platelet count <100,000/ml), hypothermia (core temperature <36°C), hypotension requiring aggressive fluid resuscitation and major criteria (≥1): septic shock with need for vasopressors or respiratory failure requiring mechanical ventilation